Clinical-stage biopharma company Aprea Therapeutics, Inc. (APRE) Monday announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for APR-1051.
Currently, in the premarket hours shares are at $8.29, up 15.78 percent from the previous close of $7.64.
The company said further to the FDA clearance, it will evaluate the next-generation inhibitor of WEE1 kinase's therapeutic activity of APR-1051 in patients, focusing on Cyclin E overexpressing cancers, including ovarian and breast cancers.
Pre-clinical studies of APR-1051 have demonstrated that the molecule has potent anti-tumor activity, along with a favorable pharmacokinetic profile. Moreover, APR-1051 has the potential to demonstrate less toxicity than other WEE1 inhibitors, the company noted. Aprea Therapeutics plans to initiate the Phase 1 ACESOT-1051 dose escalation trial to evaluate the safety, tolerability, and preliminary efficacy of APR-1051. Enrollment of the first patient in this study is expected in the first half of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.